Predicting immunotherapy reactions and safety in cancer patients
Part of Cancer clinical trials.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a solid tumor cancer confirmed by biopsy or cell sample
- You are about to receive your first dose of immunotherapy (a drug like pembrolizumab, nivolumab, ipilimumab, etc.) alone or in combination
- You have at least one tumor that can be measured on a scan (RECIST 1.1 guidelines)
- You are being treated at one of the AP-HM hospitals in Marseille and can follow the study plan
- You have signed a consent form and have health insurance coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study looks at how well immunotherapy drugs (like checkpoint inhibitors) work for different cancers. If you are already planning to receive this type of treatment, researchers want to track your outcomes and see how you do over time.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.